Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CKLIFE SCIENCES To Present New Data from Preclinical Studies of Investigational Cancer Vaccines at 2025 AACR Annual Meeting
Recommend 4 Positive 8 Negative 5 |
||||
|
||||
|
CKLIFE SCIENCES (00775.HK) announced that the Company will present new data from preclinical studies of investigational cancer vaccines at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA. The said cancer vaccines target PRAME (Preferentially Expressed Antigen in Melanoma), PD-L1 (programmed cell death ligand 1), B7-H3 (B7 homolog 3) and Claudin 6 proteins. In addition, the Company will co-present with its research collaborator two posters showcasing their Artificial Intelligence (AI)-empowered platform for designing cancer vaccines at the 2025 AACR Annual Meeting. The Company is determined to accelerate its R&D. Currently, a number of therapeutic cancer vaccines are in clinical and discovery/preclinical research stages. Amongst them, seviprotimut-L, a cancer vaccine already in the final research stage, is being tested for the adjuvant treatment of stage IIB or IIC melanoma following definitive surgical resection. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
